1
|
Kashihara T, Mori T, Nakaichi T, Nakamura S, Ito K, Kurihara H, Kusumoto M, Itami J, Yoshimoto S, Igaki H. Correlation between L-amino acid transporter 1 expression and 4-borono-2- 18 F-fluoro-phenylalanine accumulation in humans. Cancer Med 2023; 12:20564-20572. [PMID: 37881128 PMCID: PMC10660410 DOI: 10.1002/cam4.6635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 09/04/2023] [Accepted: 09/30/2023] [Indexed: 10/27/2023] Open
Abstract
BACKGROUND The correlation between L-type amino acid transporter 1 (LAT1) expression and 4-borono-2-18 F-fluoro-phenylalanine (18 F-FBPA) accumulation in humans remains unclear. This study aimed to investigate the correlation between LAT1 expression in tumor tissues and 18 F-FBPA accumulation in patients with head and neck cancer who participated in a clinical trial of 18 F-FBPA positron emission tomography (PET). METHODS Altogether, 28 patients with head and neck cancer who participated in a clinical trial of 18 F-FBPA PET at our institution between March 2012 and January 2018 were included. Correlations between standardized uptake values (SUVs); the maximum SUV (SUVmax ), the mean SUV within a 1 cm3 sphere centered at a single point, that is, the SUVmax (SUVpeak ), the minimum SUV (SUVmin ), and the intensity of LAT1 expression (maximum and minimum LAT1 expressions) were investigated. RESULTS Weak correlations were identified between SUVmax and LAT1 maximum score, SUVmin and LAT1 maximum score, and SUVmin and LAT1 minimum score (ρ = 0.427, 0.362, and 0.330, respectively). SUVmax and LAT1 minimum score, SUVpeak and LAT1 maximum score, and SUVpeak and LAT1 minimum score demonstrated moderate correlations (ρ = 0.535, 0.556, and 0.661, respectively). Boron neutron capture therapy (BNCT) was performed in 2 of the 4 patients with discrepancies between 18 F-FBPA accumulation and intensity of LAT1 expression, and the intensity of LAT1 expression was a better predictor of treatment response. CONCLUSION 18 F-FBPA accumulation and the intensity of LAT1 expression demonstrated a moderate correlation; however, LAT1 expression may be a better predictor of treatment response of BNCT in patients with discrepancies.
Collapse
Affiliation(s)
- Tairo Kashihara
- Department of Radiation OncologyNational Cancer Center HospitalTokyoJapan
- Division of Research and Development for Boron Neutron Capture TherapyNational Cancer Center Exploratory Oncology Research & Clinical Trial CenterTokyoJapan
| | - Taisuke Mori
- Department of Pathology and Clinical LaboratoriesNational Cancer Center HospitalTokyoJapan
| | - Tetsu Nakaichi
- Division of Research and Development for Boron Neutron Capture TherapyNational Cancer Center Exploratory Oncology Research & Clinical Trial CenterTokyoJapan
- Department of Medical PhysicsNational Cancer Center HospitalTokyoJapan
| | - Satoshi Nakamura
- Division of Research and Development for Boron Neutron Capture TherapyNational Cancer Center Exploratory Oncology Research & Clinical Trial CenterTokyoJapan
- Department of Medical PhysicsNational Cancer Center HospitalTokyoJapan
| | - Kimiteru Ito
- Department of Diagnostic RadiologyNational Cancer Center HospitalTokyoJapan
| | - Hiroaki Kurihara
- Department of Diagnostic RadiologyNational Cancer Center HospitalTokyoJapan
- Department of Diagnostic and Interventional RadiologyKanagawa Cancer CenterYokohamaJapan
| | - Masahiko Kusumoto
- Department of Diagnostic RadiologyNational Cancer Center HospitalTokyoJapan
| | - Jun Itami
- Department of Radiation OncologyNational Cancer Center HospitalTokyoJapan
- Shin‐Matsudo Accuracy Radiation Therapy CenterShin‐Matsudo Central General HospitalChibaJapan
| | - Seiichi Yoshimoto
- Department of Head and Neck Surgical OncologyNational Cancer Center HospitalTokyoJapan
| | - Hiroshi Igaki
- Department of Radiation OncologyNational Cancer Center HospitalTokyoJapan
- Division of Research and Development for Boron Neutron Capture TherapyNational Cancer Center Exploratory Oncology Research & Clinical Trial CenterTokyoJapan
| |
Collapse
|
2
|
Teng YC, Chen J, Zhong WB, Liu YH. Correcting for the heterogeneous boron distribution in a tumor for BNCT dose calculation. Sci Rep 2023; 13:15741. [PMID: 37735579 PMCID: PMC10514037 DOI: 10.1038/s41598-023-42284-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 09/07/2023] [Indexed: 09/23/2023] Open
Abstract
Most treatment planning systems of boron neutron capture therapy perform dose calculations based on the assumption of a homogeneous boron distribution in tumors, which leads to dose distortion due to the difference between the tumor-to-normal tissue ratio (TNR) range measured in positron emission tomography images (PET) and the target delineation in computed tomography images of the treatment plan. The heterogeneous boron distribution in the target of the treatment plan can be obtained by image fusion. This study provides a way to quantify a heterogeneous boron distribution based on PET images. Theoretically, the same mean TNR for dose calculation by homogeneous or heterogeneous boron distribution should get almost the same mean dose. However, slightly different mean doses are found due to the partial volume effect for a small target volume. The wider the boron distribution is, the higher the impact on the dose-volume histogram distribution is. Dose distribution with homogeneous boron distribution may be overestimated in low boron uptake regions by wrong boron concentration and neutron flux depression. To accurately give the tumor prescription dose and achieve better tumor control, for low dose regions of the tumor should be considered more boron neutron capture therapy treatments or combined with other treatment modalities. The heterogeneous boron distribution must be taken into consideration to have an accurate dose estimation. Therefore, the way how medical physicists and clinicians process the TNR in gross tumor volume should be refined, and the method demonstrated in the work provides a good reference.
Collapse
Affiliation(s)
- Yi-Chiao Teng
- Neuboron Therapy System Ltd., Xiamen, Fujian Province, People's Republic of China
- National Tsing Hua University, Hsinchu, 30013, Taiwan, Republic of China
| | - Jiang Chen
- Neuboron Therapy System Ltd., Xiamen, Fujian Province, People's Republic of China
- Nanjing Vocational University of Industry Technology, Nanjing, Jiangsu Province, People's Republic of China
| | - Wan-Bing Zhong
- Neuboron Therapy System Ltd., Xiamen, Fujian Province, People's Republic of China
| | - Yuan-Hao Liu
- Neuboron Therapy System Ltd., Xiamen, Fujian Province, People's Republic of China.
- Nanjing University of Aeronautics and Astronautics, Nanjing, Jiangsu Province, People's Republic of China.
- Neuboron Medtech Ltd., Nanjing, Jiangsu Province, People's Republic of China.
- Xiamen Humanity Hospital, Xiamen, Fujian Province, People's Republic of China.
| |
Collapse
|
3
|
Recent Development of Radiofluorination of Boron Agents for Boron Neutron Capture Therapy of Tumor: Creation of 18F-Labeled C-F and B-F Linkages. Pharmaceuticals (Basel) 2023; 16:ph16010093. [PMID: 36678590 PMCID: PMC9866017 DOI: 10.3390/ph16010093] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 12/27/2022] [Accepted: 01/03/2023] [Indexed: 01/11/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary therapeutic technique employing a boron agent to be delivered to the tumor site followed by the irradiation of neutrons. Biofunctional molecules/nanoparticles labeled with F-18 can provide an initial pharmacokinetic profile of patients to guide the subsequent treatment planning procedure of BNCT. Borono phenylalanine (BPA), recognized by the l-type amino acid transporter, can cross the blood-brain barrier and be accumulated in gliomas. The radiofluoro BNCT agents are reviewed by considering (1) less cytotoxicity, (2) diagnosing and therapeutic purposes, (3) aqueous solubility and extraction route, as well as (4), the trifluoroborate effect. A trifluoroborate-containing amino acid such as fluoroboronotyrosine (FBY) represents an example with both functionalities of imaging and therapeutics. Comparing with the insignificant cytotoxicity of clinical BPA with IC50 > 500 μM, FBY also shows minute toxicity with IC50 > 500 μM. [18F]FBY is a potential diagnostic agent for its tumor to normal accumulation (T/N) ratio, which ranges from 2.3 to 24.5 from positron emission tomography, whereas the T/N ratio of FBPA is greater than 2.5. Additionally, in serving as a BNCT therapeutic agent, the boron concentration of FBY accumulated in gliomas remains uncertain. The solubility of 3-BPA is better than that of BPA, as evidenced by the cerebral dose of 3.4%ID/g vs. 2.2%ID/g, respectively. While the extraction route of d-BPA differs from that of BPA, an impressive T/N ratio of 6.9 vs. 1.5 is noted. [18F]FBPA, the most common clinical boron agent, facilitates the application of BPA in clinical BNCT. In addition to [18F]FBY, [18F] trifluoroborated nucleoside analog obtained through 1,3-dipolar cycloaddition shows marked tumoral uptake of 1.5%ID/g. Other examples using electrophilic and nucleophilic fluorination on the boron compounds are also reviewed, including diboronopinacolone phenylalanine and nonsteroidal anti-inflammatory agents.
Collapse
|
4
|
Cheng X, Li F, Liang L. Boron Neutron Capture Therapy: Clinical Application and Research Progress. Curr Oncol 2022; 29:7868-7886. [PMID: 36290899 PMCID: PMC9601095 DOI: 10.3390/curroncol29100622] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 10/11/2022] [Accepted: 10/13/2022] [Indexed: 11/05/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary modality that is used to treat a variety of malignancies, using neutrons to irradiate boron-10 (10B) nuclei that have entered tumor cells to produce highly linear energy transfer (LET) alpha particles and recoil 7Li nuclei (10B [n, α] 7Li). Therefore, the most important part in BNCT is to selectively deliver a large number of 10B to tumor cells and only a small amount to normal tissue. So far, BNCT has been used in more than 2000 cases worldwide, and the efficacy of BNCT in the treatment of head and neck cancer, malignant meningioma, melanoma and hepatocellular carcinoma has been confirmed. We collected and collated clinical studies of second-generation boron delivery agents. The combination of different drugs, the mode of administration, and the combination of multiple treatments have an important impact on patient survival. We summarized the critical issues that must be addressed, with the hope that the next generation of boron delivery agents will overcome these challenges.
Collapse
Affiliation(s)
- Xiang Cheng
- Oncology Department, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei 230601, China
| | - Fanfan Li
- Oncology Department, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei 230601, China
- Correspondence: (F.L.); (L.L.); Tel.: +86-13855137365 (F.L.); +86-15905602477 (L.L.)
| | - Lizhen Liang
- Hefei Comprehensive National Science Center, Institute of Energy, Building 9, Binhu Excellence City Phase I, 16 Huayuan Avenue, Baohe District, Hefei 230031, China
- Correspondence: (F.L.); (L.L.); Tel.: +86-13855137365 (F.L.); +86-15905602477 (L.L.)
| |
Collapse
|
5
|
Kondo N, Hirano F, Temma T. Evaluation of 3-Borono-l-Phenylalanine as a Water-Soluble Boron Neutron Capture Therapy Agent. Pharmaceutics 2022; 14:pharmaceutics14051106. [PMID: 35631692 PMCID: PMC9143228 DOI: 10.3390/pharmaceutics14051106] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 05/20/2022] [Accepted: 05/20/2022] [Indexed: 02/06/2023] Open
Abstract
Although 4-borono-l-phenylalanine (4-BPA) is currently the only marketed agent available for boron neutron capture therapy (BNCT), its low water solubility raises concerns. In this study, we synthesized 3-borono-l-phenylalanine (3-BPA), a positional isomer of 4-BPA, with improved water solubility. We further evaluated its physicochemical properties, tumor accumulation, and biodistribution. The water solubility of 3-BPA was 125 g/L, which is more than 100 times higher than that of 4-BPA. Due to the high water solubility, we prepared the administration solution of 3-BPA without a solubilizer sugar, which is inevitably added to 4-BPA preparation and has adverse effects. In in vitro and in vivo experiments, boron accumulation in cancers after administration was statistically equivalent in both sugar-complexed 3-BPA and 4-BPA. Furthermore, the biodistribution of 3-BPA was comparable with that of sugar-complexed 3-BPA. Since 3-BPA has high water solubility and tumor targetability equivalent to 4-BPA, 3-BPA can replace 4-BPA in future BNCT.
Collapse
|
6
|
Hou Z, Geng C, Tang X, Tian F, Zhao S, Qi J, Shu D, Gong C. Boron concentration prediction from Compton camera image for boron neutron capture therapy based on generative adversarial network. Appl Radiat Isot 2022; 186:110302. [DOI: 10.1016/j.apradiso.2022.110302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Revised: 04/16/2022] [Accepted: 05/17/2022] [Indexed: 11/02/2022]
|
7
|
Kusumahstuti KP, Watabe T, Kitamura N, Yamamoto T. Diffuse bone marrow uptake related to granulocyte colony-stimulating factor-producing maxillary sinus carcinoma on 4-borono-2- 18F-fluoro-L-phenylalanine positron emission tomography/computed tomography. World J Nucl Med 2020; 20:188-191. [PMID: 34321973 PMCID: PMC8286009 DOI: 10.4103/wjnm.wjnm_80_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Revised: 07/21/2020] [Accepted: 08/13/2020] [Indexed: 01/12/2023] Open
Abstract
Granulocyte colony-stimulating factor (G-CSF) can be produced by tumor cells and is known to promote tumor growth, thereby potentially accelerating disease progression. Squamous cell carcinoma (SCC) at maxillary sinus is aggressive growth with poor prognosis. Maxillary sinus carcinomas are rare and can be clinically silent in the early stages or manifest with the same signs and symptoms of more common illnesses, leading to their delayed diagnosis of disease. Hypermetabolic uptake of 18F-fluorodeoxyglucose (18F-FDG) but not of 4-borono-2-18F-fluoro- L-phenylalanine (18F-FBPA), in the bone marrow of patients with G-CSF-producing tumors without bone marrow involvement during positron emission tomography (PET), has been reported. The present case report describes our first experience of bone marrow uptake in PET/computed tomography examination using18F-FBPA, high uptake seen in the bone marrow of a patient with a G-CSF-secreting SCC of the maxillary sinus that it relapsed following chemoradiation therapy and surgical resection of the tumor.
Collapse
Affiliation(s)
- Kharisma Perdani Kusumahstuti
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Molecular Imaging, Universitas Padjadjaran, General Hasan Sadikin Hospital, Bandung, Indonesia, Japan
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan.,Institute for Radiation Sciences, Osaka University, Suita, Osaka, Japan
| | - Naoya Kitamura
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nangoku, Kochi, Japan
| | - Tetsuya Yamamoto
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nangoku, Kochi, Japan
| |
Collapse
|
8
|
Balcerzyk M, De-Miguel M, Guerrero C, Fernandez B. Quantification of Boron Compound Concentration for BNCT Using Positron Emission Tomography. Cells 2020; 9:cells9092084. [PMID: 32932575 PMCID: PMC7563863 DOI: 10.3390/cells9092084] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 09/01/2020] [Accepted: 09/08/2020] [Indexed: 12/02/2022] Open
Abstract
Background: Boron neutron capture therapy requires a 2 mM 10B concentration in the tumor. The well-known BNCT patient treatment method using boronophenylalanine (BPA) as a boron-carrying agent utilizes [18F]fluoroBPA ([18F]FBPA) as an agent to qualify for treatment. Precisely, [18F]FBPA must have at least a 3:1 tumor to background tissue ratio to qualify the patient for BNCT treatment. Normal, hyperplasia, and cancer thyroids capture iodine and several other large ions, including BF4−, through a sodium-iodine symporter (NIS) expressed on the cell surface in normal conditions. In cancer, NIS is also expressed within the thyroid cell and is not functional. Methods: To visualize the thyroids and NIS, we have used a [18F]NaBF4 positron emission tomography (PET) tracer. It was injected into the tail veins of rats. The [18F]NaBF4 PET tracer was produced from NaBF4 by the isotopic exchange of natural 19F with radioactive 18F. Rats were subject to hyperplasia and tumor-inducing treatment. The NIS in thyroids was visualized by immunofluorescence staining. The boron concentration was calculated from Standard Uptake Values (SUV) in the PET/CT images and from the production data. Results: 41 MBq, 0.64 pmol of [18F]NaBF4 PET tracer that contained 0.351 mM, 53 nmol of NaBF4 was injected into the tail vein. After 17 min, the peak activity in the thyroid reached 2.3 MBq/mL (9 SUVmax). The natB concentration in the thyroid with hyperplasia reached 381 nM. Conclusions: Such an incorporation would require an additional 110 mg/kg dose of [10B]NaBF4 to reach the necessary 2 mM 10B concentration in the tumor. For future BNCT treatments of thyroid cancer, contrary to the 131I used now, there is no post-treatment radioactive decay, the patient can be immediately discharged from hospital, and there is no six-month moratorium for pregnancy. This method can be used for BNCT treatment compounds of the type R-BFn, where 1 <= n <= 3, labeled with 18F relatively easily, as in our example. A patient may undergo injection of a mixture of nonradioactive R-BFn to reach the necessary 10B concentration for BNCT treatment in the tumor together, with [18F]R-BFn for boron mapping.
Collapse
Affiliation(s)
- Marcin Balcerzyk
- Centro Nacional de Aceleradores (Universidad de Sevilla—CSIC—Junta de Andalucía), C/Thomas Alva Edison 7, 41092 Sevilla, Spain; (C.G.); (B.F.)
- Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Avda. Sánchez-Pizjuán s/n, 41009 Sevilla, Spain
- Correspondence: ; Tel.: +34-697-322-126
| | - Manuel De-Miguel
- Departamento de Citología e Histología Normal y Patológica, Universidad de Sevilla, Avda. Sánchez-Pizjuán s/n, 41009 Sevilla, Spain;
| | - Carlos Guerrero
- Centro Nacional de Aceleradores (Universidad de Sevilla—CSIC—Junta de Andalucía), C/Thomas Alva Edison 7, 41092 Sevilla, Spain; (C.G.); (B.F.)
| | - Begoña Fernandez
- Centro Nacional de Aceleradores (Universidad de Sevilla—CSIC—Junta de Andalucía), C/Thomas Alva Edison 7, 41092 Sevilla, Spain; (C.G.); (B.F.)
| |
Collapse
|
9
|
Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: Current status and future perspectives. Cancer Commun (Lond) 2020; 40:406-421. [PMID: 32805063 PMCID: PMC7494062 DOI: 10.1002/cac2.12089] [Citation(s) in RCA: 108] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 06/09/2020] [Accepted: 08/09/2020] [Indexed: 12/11/2022] Open
Abstract
The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.
Collapse
Affiliation(s)
- Mayya Alexandrovna Dymova
- Laboratory of BiotechnologyInstitute of Chemical Biology and Fundamental MedicineSiberian Branch of the Russian Academy of SciencesLavrentjeva Av. 8Novosibirsk630090Russia
| | - Sergey Yurjevich Taskaev
- Budker Institute of Nuclear PhysicsSiberian Branch of the Russian Academy of SciencesLavrentjeva Av. 11Novosibirsk630090Russia
- Laboratory of Boron Neutron Capture TherapyNovosibirsk State UniversityPirogova str. 1Novosibirsk630090Russia
| | - Vladimir Alexandrovich Richter
- Laboratory of BiotechnologyInstitute of Chemical Biology and Fundamental MedicineSiberian Branch of the Russian Academy of SciencesLavrentjeva Av. 8Novosibirsk630090Russia
| | - Elena Vladimirovna Kuligina
- Laboratory of BiotechnologyInstitute of Chemical Biology and Fundamental MedicineSiberian Branch of the Russian Academy of SciencesLavrentjeva Av. 8Novosibirsk630090Russia
| |
Collapse
|
10
|
Lo YW, Lee JC, Hu YS, Li CY, Chen YL, Lin CS, Huang WS, Lin KH, Chen YW. The importance of optimal ROIs delineation for FBPA-PET before BNCT. Appl Radiat Isot 2020; 163:109219. [PMID: 32561058 DOI: 10.1016/j.apradiso.2020.109219] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 04/27/2020] [Accepted: 05/04/2020] [Indexed: 11/27/2022]
Abstract
One of the eligible criteria for patients to receive boron neutron capture therapy (BNCT) is based on the tumour-to-normal ratio (T/N) measured by FBPA-PET. However, there is no standard protocol for normal region-of-interested delineation. With comparison of contralateral cerebrum, our study revealed the consistency (p < 0.05) and high feasibility using the cerebellum as an alternative normal tissue baseline because of its homogeneous uptake. Following RECIST version 1.1, the standard-operating-procedure (SOP) for the BNCT fulfilled the expected tumour response and tumour shrinkage rate (p < 0.05). Our modified procedure can provide more precise information for BNCT within a reasonable time.
Collapse
Affiliation(s)
- Yi-Wen Lo
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Jia-Cheng Lee
- Division of Radiotherapy, Department of Oncology Medicine, Taipei Veterans General Hospital, Taiwan
| | - Yong-Sin Hu
- Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan
| | - Chien-Ying Li
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Yi-Lun Chen
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Chi-Shuo Lin
- Division of Radiotherapy, Department of Oncology Medicine, Taipei Veterans General Hospital, Taiwan
| | - Wen-Sheng Huang
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Ko-Han Lin
- Integrated PET/MR Imaging Centre, Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
| | - Yi-Wei Chen
- Division of Radiotherapy, Department of Oncology Medicine, Taipei Veterans General Hospital, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan.
| |
Collapse
|
11
|
Lan TL, Chou FI, Lin KH, Pan PS, Lee JC, Huang WS, Liu YM, Chao Y, Chen YW. Using salvage Boron Neutron Capture Therapy (BNCT) for recurrent malignant brain tumors in Taiwan. Appl Radiat Isot 2020; 160:109105. [PMID: 32351215 DOI: 10.1016/j.apradiso.2020.109105] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2019] [Revised: 12/29/2019] [Accepted: 02/24/2020] [Indexed: 11/17/2022]
Abstract
Radiation therapy has an irreplaceable role in modern oncologic therapy, thanks to the advanced radiation techniques developed in recent decades. However, photon-resistant cases are sometimes encountered. Boron Neutron Capture Therapy (BNCT) is a highly selective radiotherapy technique due to the high tumor to tissue ratio of boronophenylalanine (BPA), the unique medication used for the BNCT treatment reaction. In this study, we report on three special patients with malignant brain tumors treated with BNCT.
Collapse
Affiliation(s)
- Tien-Li Lan
- Division of Radiotherapy, Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan.
| | - Fong-In Chou
- Nuclear Science & Technology Development Department, National Tsing-Hua University, Hsinchu, Taiwan
| | - Ko-Han Lin
- Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan
| | - Po-Shen Pan
- Department of Chemistry, Tamkang University, New Taipei City, Taiwan
| | - Jia-Cheng Lee
- Division of Radiotherapy, Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan
| | - Wen-Sheng Huang
- Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan
| | - Yu-Ming Liu
- Division of Radiotherapy, Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan
| | - Yee Chao
- Department of Oncology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan
| | - Yi-Wei Chen
- Division of Radiotherapy, Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan.
| |
Collapse
|
12
|
Evaluation of the total distribution volume of 18F-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling. Ann Nucl Med 2019; 34:155-162. [PMID: 31808134 PMCID: PMC7033086 DOI: 10.1007/s12149-019-01427-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 11/28/2019] [Indexed: 11/03/2022]
Abstract
OBJECTIVE Boron neutron capture therapy (BNCT) is a noninvasive radiation therapy method for cancer treatment. In BNCT, 4-borono-2-[18F]-fluoro-L-phenylalanine (18F-FBPA) PET has been employed to estimate 10B accumulation in target tumors and normal tissues if 10B borono-L-phenylalanine (10B-BPA) is used as a boron carrier. The purpose of the current study was to evaluate the total distribution volume (Vt) of 18F-FBPA in normal organs of healthy volunteers by kinetic analysis and to estimate boron concentration in normal organs for the therapeutic dose of 10B-BPA using obtained Vt values. METHODS Six healthy volunteers were injected with 18F-FBPA (3-5 MBq/kg), and 7 PET-CT scans were performed subsequently. 18F-FBPA radioactivity in whole blood and plasma was measured before, and eight times after the injection. PET images were analyzed by PMOD software. Twelve volumetric regions of interest including the brain, heart, right lung, spleen, liver, parotid salivary glands, esophagus, stomach, pancreas, intestines, and bone marrow were drawn manually for each subject and analyzed with the Logan plot and two Ichise multilinear analyses (MA1 and MA2). The better model was defined by several goodness-of-fit parameters and residual distribution. After Vt values had been derived, boron concentration was estimated in ppm for the 10B-BPA-fructose (10B-BPA-fr) dose 30 g 1 and 2 h post-injection using Vt and interpolated plasma activity data. RESULTS The Ichise MA2 model showed the best fit among all models. Akaike Information Criterion (AIC) was the lowest for the Ichise's MA2 in all regions (mean AIC value - 14.0) comparing to the other models (Logan plot mean AIC 31.4; Ichise MA1 model mean AIC - 4.2). Mean Vt values of the Ichise MA2 model ranged from 0.94 ± 0.14 ml/ml in the pancreas to 0.16 ± 0.02 ml/ml in the right lung. Estimated boron concentration for 10B-BPA-fr had the highest value in the pancreas (14.0 ± 1.9 ppm 1 h after, and 5.7 ± 1.7 ppm 2 h after the 18F-FBPA administration) and the lowest value in the right lung (2.4 ± 0.3 ppm 1 h, and 1.0 ± 0.3 ppm 2 h post-injection). CONCLUSION The 10B concentration in normal tissues was best estimated using Vt values of 18F-FBPA with the Ichise multilinear analysis 2 (MA2). TRAIL REGISTRY The UMIN clinical trial number: UMIN000022850.
Collapse
|
13
|
Pirouz F, Najafpour G, Jahanshahi M, Sharifzadeh Baei M. Biodistribution of calcium fructoborate as a targeting agent for boron neutron capture therapy in an experimental model of MDA-MB-231 breast cancer cells. BIOCATALYSIS AND AGRICULTURAL BIOTECHNOLOGY 2019. [DOI: 10.1016/j.bcab.2019.101389] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Zhang X, Geng C, Tang X, Bortolussi S, Shu D, Gong C, Han Y, Wu S. Assessment of long-term risks of secondary cancer in paediatric patients with brain tumours after boron neutron capture therapy. JOURNAL OF RADIOLOGICAL PROTECTION : OFFICIAL JOURNAL OF THE SOCIETY FOR RADIOLOGICAL PROTECTION 2019; 39:838-853. [PMID: 31195386 DOI: 10.1088/1361-6498/ab29a3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
This study firstly explored the risks of secondary cancer in healthy organs of Chinese paediatric patients with brain tumours after boron neutron capture therapy (BNCT). Three neutron beam irradiation geometries (i.e. right lateral, top to bottom, posterior to anterior) were adopted in treating patients with brain tumours under the clinical environment of BNCT. The concerned organs in this study were those with high cancer morbidity in China (e.g. lung, liver and stomach). The equivalent doses for these organs were calculated using Monte Carlo and anthropomorphic paediatric phantoms with Chinese physiological features. The risk of secondary cancer, characterised by the lifetime attributable risk (LAR) factor given in the BEIR VII report, was compared among the three irradiation geometries. The results showed that the LAR was lower with the PA irradiation geometry than with the two other irradiation geometries when the 2 cm diameter tumour was at a depth of 6 cm on the right side of the brain. Under the PA irradiation geometry, the LAR in the organs increased with increasing tumour volume and depth because of the long irradiation time. As the patients aged from 10-15 years old, the LAR decreased, which was related to the increased patient height and shortened life expectancy. Female patients had a relatively higher risk of secondary cancer than male patients in this study, which could be due to the thinner body thickness and the weaker protective effect on the internal organs of the female patients. In conclusion, the risks of secondary cancer in organs were related to irradiation geometries, gender, and age, indicating that the risk of secondary cancer is a personalised parameter that needs to be evaluated before administering BNCT, especially in patients with large or deep tumours.
Collapse
Affiliation(s)
- Xinxin Zhang
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Ishiwata K. 4-Borono-2- 18F-fluoro-L-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research. Ann Nucl Med 2019; 33:223-236. [PMID: 30820862 PMCID: PMC6450856 DOI: 10.1007/s12149-019-01347-8] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Accepted: 02/17/2019] [Indexed: 11/29/2022]
Abstract
4-10B-Borono-2-18F-fluoro-L-phenylalanine (18F-FBPA) was developed for monitoring the pharmacokinetics of 4-10B-borono-L-phenylalanine (10B-BPA) used in boron neutron capture therapy (BNCT) with positron emission tomography (PET). The tumor-imaging potential of 18F-FBPA was demonstrated in various animal models. Accumulation of 18F-FBPA was higher in melanomas than in non-melanoma tumors in animal models and cell cultures. 18F-FBPA was incorporated into tumors mediated mainly by L-type amino acid transporters in in vitro and in vivo models. Tumoral distribution of 18F-FBPA was primarily related to the activity of DNA synthesis. 18F-FBPA is metabolically stable but is incorporated into melanogenesis non-enzymatically. These in vitro and in vivo characteristics of 18F-FBPA corresponded well to those of 10B-BPA. Nuclear magnetic resonance and other studies using non-radioactive 19F-10/11B-FBPA also contributed to characterization. The validity and reliability of 18/19F-FBPA as an in vivo probe of 10B-BPA were confirmed by comparison of the pharmacokinetics of 18F-FBPA and 10B-BPA and direct measurement of both 18F and 10B in tumors with various doses of both probes administered by different routes and methods. Clinically, based on the kinetic parameters of dynamic 18F-FBPA PET, the estimated 10B-concentrations in tumors with continuous 10B-BPA infusion were similar to those measured directly in surgical specimens. The significance of 18F-FBPA PET was verified for the estimation of 10B-concentration and planning of BNCT. Later 18F-FBPA PET has been involved in 10B-BPA BNCT of patients with intractable tumors such as malignant brain tumors, head and neck tumors, and melanoma. Usually a static PET scan is used for screening patients for BNCT, prediction of the distribution and accumulation of 10B-BPA, and evaluation of treatment after BNCT. In some clinical trials, a tumor-to-normal tissue ratio of 18F-FBPA > 2.5 was an inclusion criterion for BNCT. Apart from BNCT, 18F-FBPA was demonstrated to be a useful PET probe for tumor diagnosis in nuclear medicine: better tumor-to-normal brain contrast compared with 11C-methionine, differentiation of recurrent and radiation necrosis after radiotherapy, and melanoma-preferential uptake. Further progress in 18F-FBPA studies is expected for more elaborate evaluation of 10B-concentrations in tumors and normal tissues for successful 10B-BPA BNCT and for radiosynthesis of 18F-FBPA to enable higher 18F-activity amounts and higher molar activities.
Collapse
Affiliation(s)
- Kiichi Ishiwata
- Southern TOHOKU Drug Discovery and Cyclotron Research Center, Southern TOHOKU Research Institute for Neuroscience, 7-61-2 Yatsuyamada, Koriyama, 963-8052, Japan. .,Department of Biofunctional Imaging, Fukushima Medical University, Fukushima, Japan.
| |
Collapse
|
16
|
Farolfi A, Ghedini P, Fanti S. Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2018; 46:217-223. [PMID: 30267115 DOI: 10.1007/s00259-018-4169-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 09/13/2018] [Indexed: 01/08/2023]
Abstract
The aim of the review is to highlight articles published in 2017 in the Annals of Nuclear Medicine, an official peer-reviewed journal of the Japanese Society of Nuclear Medicine. Among all published manuscripts during the past year, we conducted a subjective selection of the most relevant topics. Fourteen fascinating articles are included in this review, ranging in topic from preclinical to clinical arenas.
Collapse
Affiliation(s)
- Andrea Farolfi
- Metropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Via Pietro Albertoni 15, 40138, Bologna, Italy.
| | - Pietro Ghedini
- Metropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Via Pietro Albertoni 15, 40138, Bologna, Italy
| | - Stefano Fanti
- Metropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Via Pietro Albertoni 15, 40138, Bologna, Italy
| |
Collapse
|
17
|
Garcia AA, Rayevski A, Andrade-Jorge E, Trujillo-Ferrara JG. Structural and biological overview of Boron-containing amino acids in the medicinal chemistry field. Curr Med Chem 2018; 26:5077-5089. [PMID: 30259808 DOI: 10.2174/0929867325666180926150403] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2018] [Revised: 09/06/2018] [Accepted: 09/06/2018] [Indexed: 11/22/2022]
Abstract
Amino acids are the basic structural units of proteins as well as the precursors of many compounds with biological activity. The addition of boron reportedly induces changes in the chemical-biological profile of amino acids. METHODS We compiled information on the biological effect of some compounds and discuss the structure-activity relationship of the addition of boron. The specific focus presently is on borinic derivatives of α-amino acids, the specific changes in biological activity caused by the addition of a boron-containing moiety, and the identification of some attractive compounds for testing as potential new drugs. RESULTS Borinic derivatives of α-amino acids have been widely synthesized and tested as potential new therapeutic tools. The B-N (1.65 A°) or B-C (1.61 A°) or B-O (1.50 A°) bond is often key for the stability at different pHs and temperatures and activity of these compounds. The chemical features of synthesized derivatives, such as the specific moieties and the logP, polarizability and position of the boron atom are clearly linked to their pharmacodynamic and pharmacokinetic profiles. Some mechanisms of action have been suggested or demonstrated, while those responsible for other effects remain unknown. CONCLUSION The increasing number of synthetic borinic derivatives of α-amino acids as well as the recently reported crystal structures are providing new insights into the stability of these compounds at different pHs and temperatures, their interactions on drug targets, and the ring formation of five-membered heterocycles. Further research is required to clarify the ways to achieve specific synthesis, the mechanisms involved in the observed biological effect, and the toxicological profile of this type of boron-containing compounds (BCCs).
Collapse
Affiliation(s)
- Antonio Abad Garcia
- Departamento de Bioquimica y Seccion de Estudios de Posgrado e Investigación. Escuela Superior de Medicina. Plan de San Luis y Diaz Miron s/n, 11340, Mexico City. Mexico
| | - Alexey Rayevski
- Chuiko Institute of Surface Chemistry, National Academy of Science of Ukranie. 17 Generala Naumova St., 03164, Kyiv. Ukraine
| | - Erik Andrade-Jorge
- Departamento de Bioquimica y Seccion de Estudios de Posgrado e Investigacion. Escuela Superior de Medicina. Plan de San Luis y Diaz Miron s/n, 11340, Mexico City. Mexico
| | - Jose G Trujillo-Ferrara
- Departamento de Bioquímica y Sección de Estudios de Posgrado e Investigación. Escuela Superior de Medicina. Plan de San Luis y Diaz Mirón s/n, 11340, Mexico City. Mexico
| |
Collapse
|
18
|
Reliable radiosynthesis of 4-[ 10B]borono-2-[ 18F]fluoro-L-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis. Ann Nucl Med 2018; 32:463-473. [PMID: 29869193 PMCID: PMC6061177 DOI: 10.1007/s12149-018-1268-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Accepted: 05/31/2018] [Indexed: 11/18/2022]
Abstract
Objective The aim of this study was to establish a reliable and routine method for the preparation of 4-[10B]borono-2-[18F]fluoro-l-phenylalanine (l-[18F]FBPA) for boron neutron capture therapy-oriented diagnosis using positron emission tomography. Methods To produce l-[18F]FBPA by electrophilic fluorination of 4-[10B]borono-l-phenylalanine (l-BPA) with [18F]acetylhypofluorite ([18F]AcOF) via [18F]F2 derived from the 20Ne(d,α)18F nuclear reaction, several preparation parameters and characteristics of l-[18F]FBPA were investigated, including: pre-irradiation for [18F]F2 production, the carrier F2 content in the Ne target, l-BPA-to-F2 ratios, separation with high-performance liquid chromatography (HPLC) using 10 different eluents, enantiomeric purity, and residual trifluoroacetic acid used as the reaction solvent by gas chromatography-mass spectrometry. Results The activity yields and molar activities of l-[18F]FBPA (n = 38) were 1200 ± 160 MBq and 46–113 GBq/mmol, respectively, after deuteron-irradiation for 2 h. Two 5 min pre-irradiations prior to [18F]F2 production for 18F-labeling were preferable. For l-[18F]FBPA synthesis, 0.15–0.2% of carrier F2 in Ne and l-BPA-to-F2 ratios > 2 were preferable. HPLC separations with five of the 10 eluents provided injectable l-[18F]FBPA without any further formulation processing, which resulted in a synthesis time of 32 min. Among the five eluents, 1 mM phosphate-buffered saline was the eluent of choice. The l-[18F]FBPA injection was sterile and pyrogen-free, and contained very small amounts of D-enantiomer (< 0.1% of l-[18F]FBPA), l-BPA (< 1% of l-FBPA), and trifluoroacetic acid (< 0.5 ppm). Conclusions l-[18F]FBPA injection was reliably prepared by the electrophilic fluorination of l-BPA with [18F]AcOF followed by HPLC separation with 1 mM phosphate-buffered saline.
Collapse
|
19
|
Yoshimoto M, Honda N, Kurihara H, Hiroi K, Nakamura S, Ito M, Shikano N, Itami J, Fujii H. Non-invasive estimation of 10 B-4-borono-L-phenylalanine-derived boron concentration in tumors by PET using 4-borono-2- 18 F-fluoro-phenylalanine. Cancer Sci 2018; 109:1617-1626. [PMID: 29498142 PMCID: PMC5980255 DOI: 10.1111/cas.13553] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2017] [Revised: 02/19/2018] [Accepted: 02/21/2018] [Indexed: 01/02/2023] Open
Abstract
In boron neutron capture therapy (BNCT), 10 B-4-borono-L-phenylalanine (BPA) is commonly used as a 10 B carrier. PET using 4-borono-2-18 F-fluoro-phenylalanine (18 F-FBPA PET) has been performed to estimate boron concentration and predict the therapeutic effects of BNCT; however, the association between tumor uptake of 18 F-FBPA and boron concentration in tumors remains unclear. The present study investigated the transport mechanism of 18 F-FBPA and BPA, and evaluated the utility of 18 F-FBPA PET in predicting boron concentration in tumors. The transporter assay revealed that 2-aminobicyclo-(2.2.1)-heptane-2-carboxylic acid, an inhibitor of the L-type amino acid transporter, significantly inhibited 18 F-FBPA and 14 C-4-borono-L-phenylalanine (14 C-BPA) uptake in FaDu and LN-229 human cancer cells. 18 F-FBPA uptake strongly correlated with 14 C-BPA uptake in 7 human tumor cell lines (r = .93; P < .01). PET experiments demonstrated that tumor uptake of 18 F-FBPA was independent of the administration method, and uptake of 18 F-FBPA by bolus injection correlated well with BPA uptake by continuous intravenous infusion. The results of this study revealed that evaluating tumor uptake of 18 F-FBPA by PET was useful for estimating 10 B concentration in tumors.
Collapse
Affiliation(s)
- Mitsuyoshi Yoshimoto
- Division of Functional ImagingExploratory Oncology Research & Clinical Trial CenterNational Cancer CenterKashiwaChibaJapan
| | - Natsuki Honda
- Department of PharmacyNational Cancer Center HospitalTokyoJapan
| | - Hiroaki Kurihara
- Department of Diagnostic RadiologyNational Cancer Center HospitalTokyoJapan
| | - Kenta Hiroi
- Department of Diagnostic RadiologyNational Cancer Center HospitalTokyoJapan
| | - Satoshi Nakamura
- Department of Radiation OncologyNational Cancer Center HospitalTokyoJapan
| | - Masashi Ito
- Department of Radiation OncologyNational Cancer Center HospitalTokyoJapan
| | - Naoto Shikano
- Department of Radiological SciencesIbaraki Prefectural University of Health SciencesAmiIbarakiJapan
| | - Jun Itami
- Department of Radiation OncologyNational Cancer Center HospitalTokyoJapan
| | - Hirofumi Fujii
- Division of Functional ImagingExploratory Oncology Research & Clinical Trial CenterNational Cancer CenterKashiwaChibaJapan
| |
Collapse
|
20
|
Wada Y, Hirose K, Harada T, Sato M, Watanabe T, Anbai A, Hashimoto M, Takai Y. Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy. JOURNAL OF RADIATION RESEARCH 2018; 59:122-128. [PMID: 29315429 PMCID: PMC5950927 DOI: 10.1093/jrr/rrx080] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2017] [Revised: 10/30/2017] [Indexed: 06/01/2023]
Abstract
Boron neutron capture therapy (BNCT) can potentially deliver high linear energy transfer particles to tumor cells without causing severe damage to surrounding normal tissue, and may thus be beneficial for cases with characteristics of infiltrative growth, which need a wider irradiation field, such as glioblastoma multiforme. Hypoxia is an important factor contributing to resistance to anticancer therapies such as radiotherapy and chemotherapy. In this study, we investigated the impact of oxygen status on 10B uptake in glioblastoma cells in vitro in order to evaluate the potential impact of local hypoxia on BNCT. T98G and A172 glioblastoma cells were used in the present study, and we examined the influence of oxygen concentration on cell viability, mRNA expression of L-amino acid transporter 1 (LAT1), and the uptake amount of 10B-BPA. T98G and A172 glioblastoma cells became quiescent after 72 h under 1% hypoxia but remained viable. Uptake of 10B-BPA, which is one of the agents for BNCT in clinical use, decreased linearly as oxygen levels were reduced from 20% through to 10%, 3% and 1%. Hypoxia with <10% O2 significantly decreased mRNA expression of LAT1 in both cell lines, indicating that reduced uptake of 10B-BPA in glioblastoma in hypoxic conditions may be due to reduced expression of this important transporter protein. Hypoxia inhibits 10B-BPA uptake in glioblastoma cells in a linear fashion, meaning that approaches to overcoming local tumor hypoxia may be an effective method of improving the success of BNCT treatment.
Collapse
Affiliation(s)
- Yuki Wada
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
- Department of Radiology and Radiation Oncology, Akita University Graduate School of Medicine, Hospital, 1-1-1 Hondo, Akita, Akita 010-8543, Japan
| | - Katsumi Hirose
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
- Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Takaomi Harada
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
| | - Mariko Sato
- Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Tsubasa Watanabe
- Particle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, 2 Asashiro-nisi, Sennan-gun, Osaka 590-0494, Japan
| | - Akira Anbai
- Department of Radiology and Radiation Oncology, Akita University Graduate School of Medicine, Hospital, 1-1-1 Hondo, Akita, Akita 010-8543, Japan
| | - Manabu Hashimoto
- Department of Radiology and Radiation Oncology, Akita University Graduate School of Medicine, Hospital, 1-1-1 Hondo, Akita, Akita 010-8543, Japan
| | - Yoshihiro Takai
- Department of Radiation Oncology, Southern Tohoku BNCT Research Center, 7-10 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan
- Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| |
Collapse
|